Aurinia Pharmaceuticals Inc.
$17.29
The Read: Aurinia’s stock historically showed modest gains on earnings beats but struggled to rally without strong forward guidance or prescription growth, until a robust Q2 2026 beat and strategic Kezar acquisition drove an outsized 19% jump.
Price
Overlays
Panel
AUPH
Hover to view data
No Data